MXPA05011400A - Pirazoles como inhibidores de factor de necrosis tumoral. - Google Patents

Pirazoles como inhibidores de factor de necrosis tumoral.

Info

Publication number
MXPA05011400A
MXPA05011400A MXPA05011400A MXPA05011400A MXPA05011400A MX PA05011400 A MXPA05011400 A MX PA05011400A MX PA05011400 A MXPA05011400 A MX PA05011400A MX PA05011400 A MXPA05011400 A MX PA05011400A MX PA05011400 A MXPA05011400 A MX PA05011400A
Authority
MX
Mexico
Prior art keywords
alkyl
kinase
treatment
imflammations
inhbitors
Prior art date
Application number
MXPA05011400A
Other languages
English (en)
Inventor
Willard Nicole
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Publication of MXPA05011400A publication Critical patent/MXPA05011400A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invencion proporciona compuestos de la Formula (I) (ver formula (I)) y profarmacos estericos, sales o solvatos farmaceuticamente aceptables de compuestos de ese tipo; o profarmacos estericos de sales o solvatos de ese tipo; composiciones farmaceuticas que comprenden compuestos de ese tipo, su preparacion y su uso farmaceutico en el tratamiento de estados de enfermedad que pueden modularse mediante la inhibicion de quinasa p38 y/o factor de necrosis tumoral (TNF).
MXPA05011400A 2003-05-06 2004-05-05 Pirazoles como inhibidores de factor de necrosis tumoral. MXPA05011400A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46828503P 2003-05-06 2003-05-06
PCT/US2004/013875 WO2004100946A1 (en) 2003-05-06 2004-05-05 1- (2h-pyrazol -3-yl) -3yl) {4-`1- (benzoyl) -piperidin-4-ylmethyl!-phenyl}-urea derivatives and related compounds as inhbitors of p38 kinase and/or tnf inhibitors for the treatment of imflammations

Publications (1)

Publication Number Publication Date
MXPA05011400A true MXPA05011400A (es) 2005-12-12

Family

ID=28792177

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05011400A MXPA05011400A (es) 2003-05-06 2004-05-05 Pirazoles como inhibidores de factor de necrosis tumoral.

Country Status (26)

Country Link
US (1) US7541368B2 (es)
EP (1) EP1622610B1 (es)
JP (1) JP4714150B2 (es)
AT (1) ATE348610T1 (es)
AU (2) AU2004238241A1 (es)
BR (1) BRPI0409991A (es)
CA (1) CA2524043C (es)
CL (1) CL2004000965A1 (es)
CY (1) CY1107433T1 (es)
DE (1) DE602004003806T2 (es)
DK (1) DK1622610T3 (es)
ES (1) ES2277271T3 (es)
GB (1) GB0320244D0 (es)
HN (1) HN2004000150A (es)
HR (1) HRP20070020T3 (es)
JO (1) JO2473B1 (es)
MX (1) MXPA05011400A (es)
MY (1) MY140830A (es)
PA (1) PA8601901A1 (es)
PE (1) PE20050523A1 (es)
PL (1) PL1622610T3 (es)
PT (1) PT1622610E (es)
SI (1) SI1622610T1 (es)
TW (1) TWI335223B (es)
UY (1) UY28310A1 (es)
WO (1) WO2004100946A1 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7135575B2 (en) 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
ATE400567T1 (de) 2004-06-23 2008-07-15 Lilly Co Eli Kinaseinhibitoren
CA2576297C (en) 2004-08-12 2011-01-25 Pfizer Inc. Triazolopyridinylsulfanyl derivatives as p38 map kinase inhibitors
DE102004039789A1 (de) 2004-08-16 2006-03-02 Sanofi-Aventis Deutschland Gmbh Arylsubstituierte polycyclische Amine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
CA2635813C (en) 2006-01-31 2014-01-07 Array Biopharma, Inc. Urea derivatives as kinase inhibitors and methods of use thereof
EP1987022A1 (en) * 2006-02-10 2008-11-05 Pfizer Products Inc. Pyridinone pyrazole urea and pyrimidinone pyrazole urea derivatives
WO2007113005A2 (en) * 2006-04-03 2007-10-11 European Molecular Biology Laboratory (Embl) 2-substituted 3-aminosulfonyl-thiophene derivatives as aurora kinase inhibitors
CA2659155A1 (en) 2006-07-20 2008-01-24 Amgen Inc. Substituted azole aromatic heterocycles as inhibitors of 11.beta.-hsd-1
JP2010501567A (ja) 2006-08-24 2010-01-21 ノバルティス アクチエンゲゼルシャフト 代謝系、心血管系および他の障害の処置のためのステアロイル−ＣｏＡ不飽和化酵素（ＳＣＤ）阻害剤としての２−（ピラジン−２−イル）−チアゾールおよび２−（１Ｈ−ピラゾール−３−イル）チアゾール誘導体ならびに関連化合物
BRPI0718509A2 (pt) 2006-09-22 2015-09-29 Novartis Ag compostos orgânicos heterocíclicos
JP2010513403A (ja) 2006-12-20 2010-04-30 ノバルティス アーゲー Ｓｃｄ阻害剤としての２−置換５員ヘテロ環
DE102007047737A1 (de) * 2007-10-05 2009-04-30 Merck Patent Gmbh Piperidin- und Piperazinderivate
GB0818033D0 (en) 2008-10-02 2008-11-05 Respivert Ltd Novel compound
CN102256964A (zh) 2008-10-02 2011-11-23 瑞斯比维特有限公司 p38MAP激酶抑制剂
US8299074B2 (en) * 2008-12-11 2012-10-30 Respivert Ltd. P38 MAP kinase inhibitors
EP2236505A1 (de) 2009-04-03 2010-10-06 Bayer CropScience AG Acylierte Aminopyridine und - pyridazine als Insektizide
GB0905955D0 (en) 2009-04-06 2009-05-20 Respivert Ltd Novel compounds
WO2011021645A1 (ja) * 2009-08-19 2011-02-24 大日本住友製薬株式会社 ２環性ウレア誘導体、またはその薬学的に許容される塩
US9301929B2 (en) 2009-11-24 2016-04-05 Merck Sharp & Dohme Corp. Substituted biaryl derivatives and methods of use thereof
US9024041B2 (en) 2010-04-08 2015-05-05 Respivert Ltd. P38 MAP kinase inhibitors
KR101332830B1 (ko) 2012-07-05 2013-11-27 한국화학연구원 페닐우레아 유도체 또는 이의 약학적으로 허용가능한 염을 포함하는 항암감작제
TWI648282B (zh) * 2014-03-27 2019-01-21 印度商托仁特生技有限公司 新熔合咪唑苯并噻唑化合物
WO2017151409A1 (en) 2016-02-29 2017-09-08 University Of Florida Research Foundation, Incorporated Chemotherapeutic methods
CA3016196A1 (en) 2016-03-03 2017-09-08 Cornell University Small molecule ire1-alpha inhibitors
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
HRP20221196T1 (hr) 2017-10-05 2022-12-09 Fulcrum Therapeutics, Inc. Inhibitori p38 kinaze smanjuju ekspresiju dux4 i nizvodnih gena u cilju liječenja fshd
US11407771B2 (en) 2018-05-30 2022-08-09 Washington University Mitogen-activated protein kinase inhibitors, methods of making, and methods of use thereof
BR112021009610A2 (pt) * 2018-11-20 2021-08-10 Sironax Ltd composto, composição farmacêutica, uso de um composto ou composição, e, método de inibir necrose, ferroptose, rip1 humana ou indicações relacionadas

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE346600T1 (de) * 1997-12-22 2006-12-15 Bayer Pharmaceuticals Corp Inhibierung der p38 kinase-aktivität durch die verwendung von aryl- und heteroarylsubstituierten harnstoffen
US6316466B1 (en) * 1998-05-05 2001-11-13 Syntex (U.S.A.) Llc Pyrazole derivatives P-38 MAP kinase inhibitors
UA73492C2 (en) * 1999-01-19 2005-08-15 Aromatic heterocyclic compounds as antiinflammatory agents

Also Published As

Publication number Publication date
AU2010236021A1 (en) 2010-11-18
HRP20070020T3 (en) 2007-04-30
PE20050523A1 (es) 2005-07-07
PT1622610E (pt) 2007-02-28
BRPI0409991A (pt) 2006-05-09
AU2004238241A1 (en) 2004-11-25
JP2007502324A (ja) 2007-02-08
GB0320244D0 (en) 2003-10-01
HN2004000150A (es) 2008-03-03
EP1622610B1 (en) 2006-12-20
US7541368B2 (en) 2009-06-02
PL1622610T3 (pl) 2007-05-31
CY1107433T1 (el) 2012-12-19
CL2004000965A1 (es) 2005-04-22
CA2524043A1 (en) 2004-11-25
JP4714150B2 (ja) 2011-06-29
TWI335223B (en) 2011-01-01
TW200509912A (en) 2005-03-16
ES2277271T3 (es) 2007-07-01
MY140830A (en) 2010-01-29
PA8601901A1 (es) 2004-11-26
US20060063796A1 (en) 2006-03-23
SI1622610T1 (sl) 2007-04-30
DE602004003806D1 (de) 2007-02-01
DK1622610T3 (da) 2007-04-23
WO2004100946A1 (en) 2004-11-25
EP1622610A1 (en) 2006-02-08
UY28310A1 (es) 2004-11-30
JO2473B1 (en) 2009-01-20
ATE348610T1 (de) 2007-01-15
CA2524043C (en) 2009-12-29
DE602004003806T2 (de) 2007-11-22

Similar Documents

Publication Publication Date Title
MXPA05011400A (es) Pirazoles como inhibidores de factor de necrosis tumoral.
ATE371656T1 (de) Heteroaryl-pyrimidinderivate als jak-inhibitoren
MY144655A (en) Pyrimidine urea derivatives as kinase inhibitors
HK1065540A1 (en) Isoxazolyl-pyrimidines as inhibitors of src and lck protein kinases
PL1635835T3 (pl) Pochodne 2-aminopirymidyny jako inhibitory kinazy RAF
HK1087700A1 (en) Triazolopyridazines as protein kinases inhibitors
WO2002092573A3 (en) Heterocyclic substituted pyrazoles as inhibitors of src and other protein kinases
MY141739A (en) Substituted quinazoline derivatives as inhibitors of aurora kinases
MY140572A (en) Quinazolinone derivatives as parp inhibitors
IL165264A (en) Protein kinase inhibitors, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments for treating protein kinase-associated diseases
IL165262A (en) Kinase inhibitors and pharmaceutical compositions containing them
WO2005021519A3 (en) 5-phenyl-4-methyl-thiazol-2-yl-amine derivatives as inhibitors of phosphatidylinositol 3 kinase enzymes (pi3) for the treatment of inflammatory airway diseases
NO20043531L (no) Indazolforbindelser som er nyttige som proteinkinaseinhibitorer
NO20070557L (no) Ftalazinderivater som PARP-inhibitorer
UA88012C2 (uk) Похідні хіназоліндіону як інгібітори parp
MX2009011964A (es) Derivados heterociclicos pirrolo-nitrogenosos, su preparacion y uso farmaceutico.
AU2003273475A1 (en) N-(phenyl(piperidin-2-yl)methyl)benzamide derivatives, preparation thereof, and use thereof in therapy
ATE321038T1 (de) Chinolin- und chinazolinderivate und deren verwendung als farnesyl transferase inhibitoren
AU2003250471A8 (en) Pyrimidine-2,4-dione derivatives as matrix metalloproteinase inhibitors
DE602004015277D1 (de) Substituierte-1-phthalazinamine als vr-1-antagonisten
WO2004072029A3 (en) Pyrazolopyridazines useful as inhibitors of protein kinases
SE0104326D0 (sv) Therapeutic heterocycles
ATE488512T1 (de) Piperazinderivate als ccr3-hemmer
DE60220678D1 (de) Hemmer der aggregation von polyq
MXPA04000037A (es) Isoxasolil-pirimidinas como inhibidores de proteinas cinasas src y lck.

Legal Events

Date Code Title Description
FG Grant or registration